-
1
-
-
19944429145
-
Treatment challenges and investigational opportunities in autoimmune hepatitis
-
Czaja AJ, Bianchi FB, Carpenter HA, et al. Treatment challenges and investigational opportunities in autoimmune hepatitis. Hepatology 2005;41:207-15.
-
(2005)
Hepatology
, vol.41
, pp. 207-215
-
-
Czaja, A.J.1
Bianchi, F.B.2
Carpenter, H.A.3
-
2
-
-
77649253794
-
Difficult treatment decisions in autoimmune hepatitis
-
Czaja AJ. Difficult treatment decisions in autoimmune hepatitis. World J Gastroenterol 2010;16:934-47.
-
(2010)
World J Gastroenterol
, vol.16
, pp. 934-947
-
-
Czaja, A.J.1
-
3
-
-
77957893679
-
Emerging opportunities for site-specific molecular and cellular interventions in autoimmune hepatitis
-
Czaja AJ. Emerging opportunities for site-specific molecular and cellular interventions in autoimmune hepatitis. Dig Dis Sci 2010;55:2712-26.
-
(2010)
Dig Dis Sci
, vol.55
, pp. 2712-2726
-
-
Czaja, A.J.1
-
4
-
-
29444453466
-
Diverse manifestations and evolving treatments of autoimmune hepatitis
-
Czaja AJ. Diverse manifestations and evolving treatments of autoimmune hepatitis. Minerva Gastroenterol Dietol 2005;51:313-33.
-
(2005)
Minerva Gastroenterol Dietol
, vol.51
, pp. 313-333
-
-
Czaja, A.J.1
-
5
-
-
67651241981
-
Non-classical phenotypes of autoimmune hepatitis and advances in diagnosis and treatment
-
Czaja AJ, Bayraktar Y. Non-classical phenotypes of autoimmune hepatitis and advances in diagnosis and treatment. World J Gastroenterol 2009;15:2314-28.
-
(2009)
World J Gastroenterol
, vol.15
, pp. 2314-2328
-
-
Czaja, A.J.1
Bayraktar, Y.2
-
6
-
-
84877250391
-
Autoimmune hepatitis in diverse ethnic populations and geographical regions
-
Czaja AJ. Autoimmune hepatitis in diverse ethnic populations and geographical regions. Expert Rev Gastroenterol Hepatol 2013;7:365-85.
-
(2013)
Expert Rev Gastroenterol Hepatol
, vol.7
, pp. 365-385
-
-
Czaja, A.J.1
-
7
-
-
77953889134
-
Advances in the diagnosis, pathogenesis and management of autoimmune hepatitis
-
Czaja AJ, Manns MP. Advances in the diagnosis, pathogenesis and management of autoimmune hepatitis. Gastroenterology 2010;139:58-72.
-
(2010)
Gastroenterology
, vol.139
, pp. 58-72
-
-
Czaja, A.J.1
Manns, M.P.2
-
8
-
-
84866391821
-
Advances in the current treatment of autoimmune hepatitis
-
Czaja AJ. Advances in the current treatment of autoimmune hepatitis. Dig Dis Sci 2012;57:1996-2010.
-
(2012)
Dig Dis Sci
, vol.5757
, pp. 1996-2010
-
-
Czaja, A.J.1
-
9
-
-
41149153531
-
Autoimmune hepatitis. Part A: Pathogenesis
-
Czaja AJ. Autoimmune hepatitis. Part A: Pathogenesis. Expert Rev Gastroenterol Hepatol 2007;1:113-28.
-
(2007)
Expert Rev Gastroenterol Hepatol
, vol.1
, pp. 113-128
-
-
Czaja, A.J.1
-
10
-
-
41149179971
-
Genetic factors affecting the occurrence, clinical phenotype, and outcome of autoimmune hepatitis
-
Czaja AJ. Genetic factors affecting the occurrence, clinical phenotype, and outcome of autoimmune hepatitis. Clin Gastroenterol Hepatol 2008;6:379-88.
-
(2008)
Clin Gastroenterol Hepatol
, vol.6
, pp. 379-388
-
-
Czaja, A.J.1
-
12
-
-
80055088856
-
Promising pharmacological, molecular and cellular treatments of autoimmune hepatitis
-
Czaja AJ. Promising pharmacological, molecular and cellular treatments of autoimmune hepatitis. Curr Pharm Des 2011;17:3120-40.
-
(2011)
Curr Pharm des
, vol.17
, pp. 3120-3140
-
-
Czaja, A.J.1
-
13
-
-
84866397703
-
Nonstandard drugs and feasible new interventions for autoimmune hepatitis. Part i
-
Czaja AJ. Nonstandard drugs and feasible new interventions for autoimmune hepatitis. Part I. Inflamm Allergy Drug Targets 2012;11:337-50.
-
(2012)
Inflamm Allergy Drug Targets
, vol.11
, pp. 337-350
-
-
Czaja, A.J.1
-
14
-
-
84867739910
-
Nonstandard drugs and feasible new interventions for autoimmune hepatitis. Part II
-
Czaja AJ. Nonstandard drugs and feasible new interventions for autoimmune hepatitis. Part II. Inflamm Allergy Drug Targets 2012;11:351-63.
-
(2012)
Inflamm Allergy Drug Targets
, vol.11
, pp. 351-363
-
-
Czaja, A.J.1
-
15
-
-
84866770664
-
Autoimmune hepatitis: Focusing on treatments other than steroids
-
Czaja AJ. Autoimmune hepatitis: Focusing on treatments other than steroids. Can J Gastroenterol 2012;26:615-20.
-
(2012)
Can J Gastroenterol
, vol.26
, pp. 615-620
-
-
Czaja, A.J.1
-
16
-
-
84876691081
-
Acute and acute severe (fulminant) autoimmune hepatitis
-
Czaja AJ. Acute and acute severe (fulminant) autoimmune hepatitis. Dig Dis Sci 2013;58:897-914.
-
(2013)
Dig Dis Sci
, vol.58
, pp. 897-914
-
-
Czaja, A.J.1
-
17
-
-
0036083869
-
Prognosis of symptomatic versus asymptomatic autoimmune hepatitis: A study of 68 patients
-
Kogan J, Safadi R, Ashur Y, Shouval D, Ilan Y. Prognosis of symptomatic versus asymptomatic autoimmune hepatitis: A study of 68 patients. J Clin Gastroenterol 2002;35:75-81.
-
(2002)
J Clin Gastroenterol
, vol.35
, pp. 75-81
-
-
Kogan, J.1
Safadi, R.2
Ashur, Y.3
Shouval, D.4
Ilan, Y.5
-
18
-
-
21344453508
-
Autoimmune hepatitis: Effect of symptoms and cirrhosis on natural history and outcome
-
Feld JJ, Dinh H, Arenovich T, et al. Autoimmune hepatitis: Effect of symptoms and cirrhosis on natural history and outcome. Hepatology 2005;42:53-62.
-
(2005)
Hepatology
, vol.42
, pp. 53-62
-
-
Feld, J.J.1
Dinh, H.2
Arenovich, T.3
-
19
-
-
0030795419
-
A novel histological lesion in glucocorticoid-responsive chronic hepatitis
-
Pratt DS, Fawaz KA, Rabson A, Dellelis R, Kaplan MM. A novel histological lesion in glucocorticoid-responsive chronic hepatitis. Gastroenterology 1997;113:664-8.
-
(1997)
Gastroenterology
, vol.113
, pp. 664-668
-
-
Pratt, D.S.1
Fawaz, K.A.2
Rabson, A.3
Dellelis, R.4
Kaplan, M.M.5
-
20
-
-
0038748278
-
Clinicopathological features of acute-onset autoimmune hepatitis
-
Okano N, Yamamoto K, Sakaguchi K, et al. Clinicopathological features of acute-onset autoimmune hepatitis. Hepatol Res 2003;25:263-70.
-
(2003)
Hepatol Res
, vol.25
, pp. 263-270
-
-
Okano, N.1
Yamamoto, K.2
Sakaguchi, K.3
-
21
-
-
3042535422
-
Fulminant hepatic failure as the initial presentation of acute autoimmune hepatitis
-
Kessler WR, Cummings OW, Eckert G, et al. Fulminant hepatic failure as the initial presentation of acute autoimmune hepatitis. Clin Gastroenterol Hepatol 2004;2:625-31.
-
(2004)
Clin Gastroenterol Hepatol
, vol.2
, pp. 625-631
-
-
Kessler, W.R.1
Cummings, O.W.2
Eckert, G.3
-
23
-
-
34548165103
-
Clinical features of Japanese type 1 autoimmune hepatitis patients with zone III necrosis
-
Miyake Y, Iwasaki Y, Terada R, et al. Clinical features of Japanese type 1 autoimmune hepatitis patients with zone III necrosis. Hepatol Res 2007;37:801-5.
-
(2007)
Hepatol Res
, vol.37
, pp. 801-805
-
-
Miyake, Y.1
Iwasaki, Y.2
Terada, R.3
-
24
-
-
0034807020
-
Autoimmune hepatitis with incidental histologic features of bile duct injury
-
Czaja AJ, Carpenter HA. Autoimmune hepatitis with incidental histologic features of bile duct injury. Hepatology 2001;34:659-65.
-
(2001)
Hepatology
, vol.34
, pp. 659-665
-
-
Czaja, A.J.1
Carpenter, H.A.2
-
25
-
-
4444319614
-
Diagnostic and therapeutic implications of bile duct injury in autoimmune hepatitis
-
Czaja AJ, Muratori P, Muratori L, Carpenter HA, Bianchi FB. Diagnostic and therapeutic implications of bile duct injury in autoimmune hepatitis. Liver Int 2004;24:322-9.
-
(2004)
Liver Int
, vol.24
, pp. 322-329
-
-
Czaja, A.J.1
Muratori, P.2
Muratori, L.3
Carpenter, H.A.4
Bianchi, F.B.5
-
26
-
-
0032718310
-
International Autoimmune Hepatitis Group Report: Review of criteria for diagnosis of autoimmune hepatitis
-
Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Report: Review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999;31:929-38.
-
(1999)
J Hepatol
, vol.31
, pp. 929-938
-
-
Alvarez, F.1
Berg, P.A.2
Bianchi, F.B.3
-
27
-
-
47149112922
-
Simplified criteria for the diagnosis of autoimmune hepatitis
-
Hennes EM, Zeniya M, Czaja AJ, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008;48:169-76.
-
(2008)
Hepatology
, vol.48
, pp. 169-176
-
-
Hennes, E.M.1
Zeniya, M.2
Czaja, A.J.3
-
28
-
-
3242757530
-
Type 1 autoimmune hepatitis: Patterns of clinical presentation and differential diagnosis of the 'acute' type
-
Ferrari R, Pappas G, Agostinelli D, et al. Type 1 autoimmune hepatitis: Patterns of clinical presentation and differential diagnosis of the 'acute' type. QJM 2004;97:407-12.
-
(2004)
QJM
, vol.97
, pp. 407-412
-
-
Ferrari, R.1
Pappas, G.2
Agostinelli, D.3
-
29
-
-
79251513939
-
Autoimmune acute liver failure: Proposed clinical and histological criteria
-
Stravitz RT, Lefkowitch JH, Fontana RJ, et al. Autoimmune acute liver failure: Proposed clinical and histological criteria. Hepatology 2011;53:517-26.
-
(2011)
Hepatology
, vol.53
, pp. 517-526
-
-
Stravitz, R.T.1
Lefkowitch, J.H.2
Fontana, R.J.3
-
30
-
-
84866384808
-
Diagnosis, pathogenesis, and treatment of autoimmune hepatitis after liver transplantation
-
Czaja AJ. Diagnosis, pathogenesis, and treatment of autoimmune hepatitis after liver transplantation. Dig Dis Sci 2012;57:2248-66.
-
(2012)
Dig Dis Sci
, vol.57
, pp. 2248-2266
-
-
Czaja, A.J.1
-
31
-
-
0035153638
-
Clinical characteristics of autoimmune hepatitis with histological features of acute hepatitis
-
Abe M, Hiasa Y, Masumoto T, et al. Clinical characteristics of autoimmune hepatitis with histological features of acute hepatitis. Hepatol Res 2001;21:213-9.
-
(2001)
Hepatol Res
, vol.21
, pp. 213-219
-
-
Abe, M.1
Hiasa, Y.2
Masumoto, T.3
-
32
-
-
58149197665
-
Precise histological evaluation of liver biopsy specimen is indispensable for diagnosis and treatment of acute-onset autoimmune hepatitis
-
Fujiwara K, Fukuda Y, Yokosuka O. Precise histological evaluation of liver biopsy specimen is indispensable for diagnosis and treatment of acute-onset autoimmune hepatitis. J Gastroenterol 2008;43:951-8.
-
(2008)
J Gastroenterol
, vol.43
, pp. 951-958
-
-
Fujiwara, K.1
Fukuda, Y.2
Yokosuka, O.3
-
33
-
-
73149085031
-
Autoimmune hepatitis with acute presentation in Japan
-
Miyake Y, Iwasaki Y, Kobashi H, et al. Autoimmune hepatitis with acute presentation in Japan. Dig Liver Dis 2010;42:51-4.
-
(2010)
Dig Liver Dis
, vol.42
, pp. 51-54
-
-
Miyake, Y.1
Iwasaki, Y.2
Kobashi, H.3
-
34
-
-
79954414704
-
Clinicopathological features of severe and fulminant forms of autoimmune hepatitis
-
Yasui S, Fujiwara K, Yonemitsu Y, et al. Clinicopathological features of severe and fulminant forms of autoimmune hepatitis. J Gastroenterol 2011;46:378-90.
-
(2011)
J Gastroenterol
, vol.46
, pp. 378-390
-
-
Yasui, S.1
Fujiwara, K.2
Yonemitsu, Y.3
-
35
-
-
33846805723
-
Clinicopathologic features of the severe form of acute type 1 autoimmune hepatitis
-
Abe M, Onji M, Kawai-Ninomiya K, et al. Clinicopathologic features of the severe form of acute type 1 autoimmune hepatitis. Clin Gastroenterol Hepatol 2007;5:255-8.
-
(2007)
Clin Gastroenterol Hepatol
, vol.5
, pp. 255-258
-
-
Abe, M.1
Onji, M.2
Kawai-Ninomiya, K.3
-
36
-
-
34547394251
-
Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis
-
Ichai P, Duclos-Vallee JC, Guettier C, et al. Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis. Liver Transpl 2007;13:996-1003.
-
(2007)
Liver Transpl
, vol.13
, pp. 996-1003
-
-
Ichai, P.1
Duclos-Vallee, J.C.2
Guettier, C.3
-
37
-
-
0023812878
-
Features reflective of early prognosis in corticosteroid-treated severe autoimmune chronic active hepatitis
-
Czaja AJ, Rakela J, Ludwig J. Features reflective of early prognosis in corticosteroid-treated severe autoimmune chronic active hepatitis. Gastroenterology 1988;95:448-53.
-
(1988)
Gastroenterology
, vol.95
, pp. 448-453
-
-
Czaja, A.J.1
Rakela, J.2
Ludwig, J.3
-
38
-
-
11844269814
-
Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids
-
Czock D, Keller F, Rasche FM, Haussler U. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet 2005;44:61-98.
-
(2005)
Clin Pharmacokinet
, vol.44
, pp. 61-98
-
-
Czock, D.1
Keller, F.2
Rasche, F.M.3
Haussler, U.4
-
39
-
-
84867492451
-
Drug choices in autoimmune hepatitis: Part A - Steroids
-
Czaja AJ. Drug choices in autoimmune hepatitis: Part A - steroids. Expert Rev Gastroenterol Hepatol 2012;6:603-15.
-
(2012)
Expert Rev Gastroenterol Hepatol
, vol.6
, pp. 603-615
-
-
Czaja, A.J.1
-
40
-
-
58049088632
-
Clinical epidemiology of fulminant hepatitis in Japan
-
Takikawa Y, Suzuki K. Clinical epidemiology of fulminant hepatitis in Japan. Hepatol Res 2008;38(Suppl 1):S14-8.
-
(2008)
Hepatol Res
, vol.38
, Issue.SUPPL. 1
-
-
Takikawa, Y.1
Suzuki, K.2
-
41
-
-
0042332240
-
Liver transplantation for autoimmune hepatitis: Fulminant versus chronic hepatitis presentation
-
Nunez-Martinez O, De la Cruz G, Salcedo M, et al. Liver transplantation for autoimmune hepatitis: Fulminant versus chronic hepatitis presentation. Transplant Proc 2003;35:1857-8.
-
(2003)
Transplant Proc
, vol.35
, pp. 1857-1858
-
-
Nunez-Martinez, O.1
De La Cruz, G.2
Salcedo, M.3
-
42
-
-
34547419539
-
Corticosteroids or not in severe acute or fulminant autoimmune hepatitis: Therapeutic brinksmanship and the point beyond salvation
-
Czaja AJ. Corticosteroids or not in severe acute or fulminant autoimmune hepatitis: Therapeutic brinksmanship and the point beyond salvation. Liver Transpl 2007;13:953-5.
-
(2007)
Liver Transpl
, vol.13
, pp. 953-955
-
-
Czaja, A.J.1
-
43
-
-
59649086033
-
Features and consequences of untreated type 1 autoimmune hepatitis
-
Czaja AJ. Features and consequences of untreated type 1 autoimmune hepatitis. Liver Int 2009;29:816-23.
-
(2009)
Liver Int
, vol.29
, pp. 816-823
-
-
Czaja, A.J.1
-
44
-
-
0021246718
-
Manifestations of nonsuppurative cholangitis in chronic hepatobiliary diseases: Morphologic spectrum, clinical correlations and terminology
-
Ludwig J, Czaja AJ, Dickson ER, LaRusso NF, Wiesner RH. Manifestations of nonsuppurative cholangitis in chronic hepatobiliary diseases: Morphologic spectrum, clinical correlations and terminology. Liver 1984;4:105-16.
-
(1984)
Liver
, vol.4
, pp. 105-116
-
-
Ludwig, J.1
Czaja, A.J.2
Dickson, E.R.3
Larusso, N.F.4
Wiesner, R.H.5
-
45
-
-
0034034595
-
Autoimmune cholangitis within the spectrum of autoimmune liver disease
-
Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Autoimmune cholangitis within the spectrum of autoimmune liver disease. Hepatology 2000;31:1231-8.
-
(2000)
Hepatology
, vol.31
, pp. 1231-1238
-
-
Czaja, A.J.1
Carpenter, H.A.2
Santrach, P.J.3
Moore, S.B.4
-
46
-
-
0027146326
-
Sensitivity, specificity, and predictability of biopsy interpretations in chronic hepatitis
-
Czaja AJ, Carpenter HA. Sensitivity, specificity, and predictability of biopsy interpretations in chronic hepatitis. Gastroenterology 1993;105:1824-32.
-
(1993)
Gastroenterology
, vol.105
, pp. 1824-1832
-
-
Czaja, A.J.1
Carpenter, H.A.2
-
47
-
-
84876334054
-
The overlap syndromes of autoimmune hepatitis
-
Czaja AJ. The overlap syndromes of autoimmune hepatitis. Dig Dis Sci 2013;58:326-43.
-
(2013)
Dig Dis Sci
, vol.58
, pp. 326-343
-
-
Czaja, A.J.1
-
48
-
-
78751572618
-
Overlap syndromes: The International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue
-
Boberg KM, Chapman RW, Hirschfield GM, et al. Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. J Hepatol 2011;54:374-85.
-
(2011)
J Hepatol
, vol.54
, pp. 374-385
-
-
Boberg, K.M.1
Chapman, R.W.2
Hirschfield, G.M.3
-
49
-
-
77952711598
-
Practice guidelines of the American association for the study of liver diseases. Diagnosis and management of autoimmune hepatitis
-
Manns MP, Czaja AJ, Gorham JD, et al. Practice Guidelines of the American Association for the Study of Liver Diseases. Diagnosis and management of autoimmune hepatitis. Hepatology 2010;51:2193-213.
-
(2010)
Hepatology
, vol.51
, pp. 2193-2213
-
-
Manns, M.P.1
Czaja, A.J.2
Gorham, J.D.3
-
50
-
-
0035117791
-
Duration of immunosuppressive therapy in autoimmune hepatitis
-
Kanzler S, Gerken G, Lohr H, et al. Duration of immunosuppressive therapy in autoimmune hepatitis. J Hepatol 2001;34:354-5.
-
(2001)
J Hepatol
, vol.34
, pp. 354-355
-
-
Kanzler, S.1
Gerken, G.2
Lohr, H.3
-
51
-
-
67349145925
-
Rapidity of treatment response and outcome in type 1 autoimmune hepatitis
-
Czaja AJ. Rapidity of treatment response and outcome in type 1 autoimmune hepatitis. J Hepatol 2009;51:161-7.
-
(2009)
J Hepatol
, vol.51
, pp. 161-167
-
-
Czaja, A.J.1
-
52
-
-
1642285767
-
Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis
-
Czaja AJ, Carpenter HA. Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. J Hepatol 2004;40:646-52.
-
(2004)
J Hepatol
, vol.40
, pp. 646-652
-
-
Czaja, A.J.1
Carpenter, H.A.2
-
53
-
-
0030065386
-
Prognosis of histological cirrhosis in type 1 autoimmune hepatitis
-
Roberts SK, Therneau TM, Czaja AJ. Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. Gastroenterology 1996;110:848-57.
-
(1996)
Gastroenterology
, vol.110
, pp. 848-857
-
-
Roberts, S.K.1
Therneau, T.M.2
Czaja, A.J.3
-
54
-
-
0035002235
-
Long-term management and prognosis of autoimmune hepatitis (AIH): A single center experience
-
44-8
-
Kanzler S, Lohr H, Gerken G, Galle PR, Lohse AW. Long-term management and prognosis of autoimmune hepatitis (AIH): A single center experience. Z Gastroenterol 2001;39:339-41, 44-8.
-
(2001)
Z Gastroenterol
, vol.39
, pp. 339-341
-
-
Kanzler, S.1
Lohr, H.2
Gerken, G.3
Galle, P.R.4
Lohse, A.W.5
-
55
-
-
33748653157
-
Type i autoimmune hepatitis: Clinical course and outcome in an Italian multicentre study
-
Floreani A, Niro G, Rosa Rizzotto E, et al. Type I autoimmune hepatitis: Clinical course and outcome in an Italian multicentre study. Aliment Pharmacol Ther 2006;24:1051-7.
-
(2006)
Aliment Pharmacol Ther
, vol.24
, pp. 1051-1057
-
-
Floreani, A.1
Niro, G.2
Rosa Rizzotto, E.3
-
56
-
-
49849097120
-
Favorable outcomes of autoimmune hepatitis in a community clinic setting
-
Seo S, Toutounjian R, Conrad A, Blatt L, Tong MJ. Favorable outcomes of autoimmune hepatitis in a community clinic setting. J Gastroenterol Hepatol 2008;23:1410-4.
-
(2008)
J Gastroenterol Hepatol
, vol.23
, pp. 1410-1414
-
-
Seo, S.1
Toutounjian, R.2
Conrad, A.3
Blatt, L.4
Tong, M.J.5
-
57
-
-
79958162463
-
Long-term outcomes of patients with autoimmune hepatitis managed at a nontransplant center
-
Hoeroldt B, McFarlane E, Dube A, et al. Long-term outcomes of patients with autoimmune hepatitis managed at a nontransplant center. Gastroenterology 2011;140:1980-9.
-
(2011)
Gastroenterology
, vol.140
, pp. 1980-1989
-
-
Hoeroldt, B.1
McFarlane, E.2
Dube, A.3
-
58
-
-
4444250848
-
Factors predicting relapse and poor outcome in type i autoimmune hepatitis: Role of cirrhosis development, patterns of transaminases during remission and plasma cell activity in the liver biopsy
-
Verma S, Gunuwan B, Mendler M, Govindrajan S, Redeker A. Factors predicting relapse and poor outcome in type I autoimmune hepatitis: Role of cirrhosis development, patterns of transaminases during remission and plasma cell activity in the liver biopsy. Am J Gastroenterol 2004;99:1510-6.
-
(2004)
Am J Gastroenterol
, vol.99
, pp. 1510-1516
-
-
Verma, S.1
Gunuwan, B.2
Mendler, M.3
Govindrajan, S.4
Redeker, A.5
-
59
-
-
27744580616
-
Persistent normalization of serum alanine aminotransferase levels improves the prognosis of type 1 autoimmune hepatitis
-
Miyake Y, Iwasaki Y, Terada R, et al. Persistent normalization of serum alanine aminotransferase levels improves the prognosis of type 1 autoimmune hepatitis. J Hepatol 2005;43:951-7.
-
(2005)
J Hepatol
, vol.43
, pp. 951-957
-
-
Miyake, Y.1
Iwasaki, Y.2
Terada, R.3
-
60
-
-
34247860578
-
Improving the end point of corticosteroid therapy in type 1 autoimmune hepatitis to reduce the frequency of relapse
-
Montano-Loza AJ, Carpenter HA, Czaja AJ. Improving the end point of corticosteroid therapy in type 1 autoimmune hepatitis to reduce the frequency of relapse. Am J Gastroenterol 2007;102:1005-12.
-
(2007)
Am J Gastroenterol
, vol.102
, pp. 1005-1012
-
-
Montano-Loza, A.J.1
Carpenter, H.A.2
Czaja, A.J.3
-
61
-
-
54549127081
-
Serologic markers compared with liver biopsy for monitoring disease activity in autoimmune hepatitis
-
Luth S, Herkel J, Kanzler S, et al. Serologic markers compared with liver biopsy for monitoring disease activity in autoimmune hepatitis. J Clin Gastroenterol 2008;42:926-30.
-
(2008)
J Clin Gastroenterol
, vol.42
, pp. 926-930
-
-
Luth, S.1
Herkel, J.2
Kanzler, S.3
-
62
-
-
84866393237
-
Systematic review: Managing suboptimal treatment responses in autoimmune hepatitis with conventional and nonstandard drugs
-
Selvarajah V, Montano-Loza AJ, Czaja AJ. Systematic review: Managing suboptimal treatment responses in autoimmune hepatitis with conventional and nonstandard drugs. Aliment Pharmacol Ther 2012;36:691-707.
-
(2012)
Aliment Pharmacol Ther
, vol.36
, pp. 691-707
-
-
Selvarajah, V.1
Montano-Loza, A.J.2
Czaja, A.J.3
-
63
-
-
0036211577
-
Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: A retrospective analysis
-
Czaja AJ, Menon KV, Carpenter HA. Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: A retrospective analysis. Hepatology 2002;35:890-7.
-
(2002)
Hepatology
, vol.35
, pp. 890-897
-
-
Czaja, A.J.1
Menon, K.V.2
Carpenter, H.A.3
-
64
-
-
0029130857
-
Azathioprine for long-term maintenance of remission in autoimmune hepatitis
-
Johnson PJ, McFarlane IG, Williams R. Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N Engl J Med 1995;333:958-63.
-
(1995)
N Engl J Med
, vol.333
, pp. 958-963
-
-
Johnson, P.J.1
McFarlane, I.G.2
Williams, R.3
-
65
-
-
0025298505
-
Low-dose corticosteroid therapy after multiple relapses of severe HBsAg-negative chronic active hepatitis
-
Czaja AJ. Low-dose corticosteroid therapy after multiple relapses of severe HBsAg-negative chronic active hepatitis. Hepatology 1990;11:1044-9.
-
(1990)
Hepatology
, vol.11
, pp. 1044-1049
-
-
Czaja, A.J.1
-
66
-
-
22844437295
-
Autoimmune hepatitis type 1: Safety and efficacy of prolonged medical therapy
-
Seela S, Sheela H, Boyer JL. Autoimmune hepatitis type 1: Safety and efficacy of prolonged medical therapy. Liver Int 2005;25:734-9.
-
(2005)
Liver Int
, vol.25
, pp. 734-739
-
-
Seela, S.1
Sheela, H.2
Boyer, J.L.3
-
67
-
-
84871211618
-
Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remission
-
van Gerven NM, Verwer BJ, Witte BI, et al. Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remission. J Hepatol 2013;58:141-7.
-
(2013)
J Hepatol
, vol.58
, pp. 141-147
-
-
Van Gerven, N.M.1
Verwer, B.J.2
Witte, B.I.3
-
68
-
-
0021217938
-
Complete resolution of inflammatory activity following corticosteroid treatment of HBsAgnegative chronic active hepatitis
-
Czaja AJ, Davis GL, Ludwig J, Taswell HF. Complete resolution of inflammatory activity following corticosteroid treatment of HBsAgnegative chronic active hepatitis. Hepatology 1984;4:622-7.
-
(1984)
Hepatology
, vol.4
, pp. 622-627
-
-
Czaja, A.J.1
Davis, G.L.2
Ludwig, J.3
Taswell, H.F.4
-
69
-
-
34047223229
-
Consequences of treatment withdrawal in type 1 autoimmune hepatitis
-
Montano-Loza AJ, Carpenter HA, Czaja AJ. Consequences of treatment withdrawal in type 1 autoimmune hepatitis. Liver Int 2007;27:507-15.
-
(2007)
Liver Int
, vol.27
, pp. 507-515
-
-
Montano-Loza, A.J.1
Carpenter, H.A.2
Czaja, A.J.3
-
70
-
-
36349017310
-
Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the Model of End-stage Liver Disease
-
Montano-Loza AJ, Carpenter HA, Czaja AJ. Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the Model of End-stage Liver Disease. Hepatology 2007;46:1138-45.
-
(2007)
Hepatology
, vol.46
, pp. 1138-1145
-
-
Montano-Loza, A.J.1
Carpenter, H.A.2
Czaja, A.J.3
-
71
-
-
79952203791
-
Early predictors of corticosteroid treatment failure in icteric presentations of autoimmune hepatitis
-
Yeoman AD, Westbrook RH, Zen Y, et al. Early predictors of corticosteroid treatment failure in icteric presentations of autoimmune hepatitis. Hepatology 2011;53:926-34.
-
(2011)
Hepatology
, vol.53
, pp. 926-934
-
-
Yeoman, A.D.1
Westbrook, R.H.2
Zen, Y.3
-
72
-
-
33645219865
-
Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly
-
Czaja AJ, Carpenter HA. Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly. Hepatology 2006;43:532-8.
-
(2006)
Hepatology
, vol.43
, pp. 532-538
-
-
Czaja, A.J.1
Carpenter, H.A.2
-
73
-
-
77954423957
-
Autoantibodies as prognostic markers in autoimmune liver disease
-
Czaja AJ. Autoantibodies as prognostic markers in autoimmune liver disease. Dig Dis Sci 2010;55:2144-61.
-
(2010)
Dig Dis Sci
, vol.55
, pp. 2144-2161
-
-
Czaja, A.J.1
-
74
-
-
83255170463
-
Prognostic implications of antibodies to Ro/SSA and soluble liver antigen in type 1 autoimmune hepatitis
-
Montano-Loza AJ, Shums Z, Norman GL, Czaja AJ. Prognostic implications of antibodies to Ro/SSA and soluble liver antigen in type 1 autoimmune hepatitis. Liver Int 2012;32:85-92.
-
(2012)
Liver Int
, vol.32
, pp. 85-92
-
-
Montano-Loza, A.J.1
Shums, Z.2
Norman, G.L.3
Czaja, A.J.4
-
75
-
-
0031032711
-
Associations between alleles of the major histocompatibility complex and type 1 autoimmune hepatitis
-
Czaja AJ, Strettell MD, Thomson LJ, et al. Associations between alleles of the major histocompatibility complex and type 1 autoimmune hepatitis. Hepatology 1997;25:317-23.
-
(1997)
Hepatology
, vol.25
, pp. 317-323
-
-
Czaja, A.J.1
Strettell, M.D.2
Thomson, L.J.3
-
76
-
-
0036174801
-
Antibodies to soluble liver antigen/liver pancreas and HLA risk factors for type 1 autoimmune hepatitis
-
Czaja AJ, Donaldson PT, Lohse AW. Antibodies to soluble liver antigen/liver pancreas and HLA risk factors for type 1 autoimmune hepatitis. Am J Gastroenterol 2002;97:413-9.
-
(2002)
Am J Gastroenterol
, vol.97
, pp. 413-419
-
-
Czaja, A.J.1
Donaldson, P.T.2
Lohse, A.W.3
-
77
-
-
84872168522
-
Antibodies to soluble liver antigen in patients with various liver diseases: A multicentre study
-
Efe C, Ozaslan E, Wahlin S, et al. Antibodies to soluble liver antigen in patients with various liver diseases: A multicentre study. Liver Int 2013;33:190-6.
-
(2013)
Liver Int
, vol.33
, pp. 190-196
-
-
Efe, C.1
Ozaslan, E.2
Wahlin, S.3
-
78
-
-
18244366619
-
Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease
-
Ma Y, Okamoto M, Thomas MG, et al. Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease. Hepatology 2002;35:658-64.
-
(2002)
Hepatology
, vol.35
, pp. 658-664
-
-
Ma, Y.1
Okamoto, M.2
Thomas, M.G.3
-
79
-
-
0036070963
-
Establishment of standardised SLA/LP immunoassays: Specificity for autoimmune hepatitis, worldwide occurrence, and clinical characteristics
-
Baeres M, Herkel J, Czaja AJ, et al. Establishment of standardised SLA/LP immunoassays: Specificity for autoimmune hepatitis, worldwide occurrence, and clinical characteristics. Gut 2002;51:259-64.
-
(2002)
Gut
, vol.51
, pp. 259-264
-
-
Baeres, M.1
Herkel, J.2
Czaja, A.J.3
-
80
-
-
2442481067
-
Alpha-actinin revisited: A fresh look at an old player
-
Otey CA, Carpen O. Alpha-actinin revisited: A fresh look at an old player. Cell Motil Cytoskeleton 2004;58:104-11.
-
(2004)
Cell Motil Cytoskeleton
, vol.58
, pp. 104-111
-
-
Otey, C.A.1
Carpen, O.2
-
81
-
-
33751120137
-
Double reactivity against actin and alpha-actinin defines a severe form of autoimmune hepatitis type 1
-
Gueguen P, Dalekos G, Nousbaum JB, et al. Double reactivity against actin and alpha-actinin defines a severe form of autoimmune hepatitis type 1. J Clin Immunol 2006;26:495-505.
-
(2006)
J Clin Immunol
, vol.26
, pp. 495-505
-
-
Gueguen, P.1
Dalekos, G.2
Nousbaum, J.B.3
-
82
-
-
84867526442
-
Drug choices in autoimmune hepatitis: Part B - Nonsteroids
-
Czaja AJ. Drug choices in autoimmune hepatitis: Part B - nonsteroids. Expert Rev Gastroenterol Hepatol 2012;6:617-35.
-
(2012)
Expert Rev Gastroenterol Hepatol
, vol.6
, pp. 617-635
-
-
Czaja, A.J.1
-
83
-
-
37549041628
-
In utero exposure to mycophenolate mofetil: A characteristic phenotype?
-
Perez-Aytes A, Ledo A, Boso V, et al. In utero exposure to mycophenolate mofetil: A characteristic phenotype? Am J Med Genet A 2008;146A:1-7.
-
(2008)
Am J Med Genet A
, vol.146
, pp. 1-7
-
-
Perez-Aytes, A.1
Ledo, A.2
Boso, V.3
-
84
-
-
77957345684
-
Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis
-
Manns MP, Woynarowski M, Kreisel W, et al. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology 2010;139:1198-206.
-
(2010)
Gastroenterology
, vol.139
, pp. 1198-1206
-
-
Manns, M.P.1
Woynarowski, M.2
Kreisel, W.3
-
85
-
-
0034321507
-
Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis
-
Czaja AJ, Lindor KD. Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis. Gastroenterology 2000;119:1312-6.
-
(2000)
Gastroenterology
, vol.119
, pp. 1312-1316
-
-
Czaja, A.J.1
Lindor, K.D.2
-
86
-
-
0347598081
-
Side effects of budesonide in liver cirrhosis due to chronic autoimmune hepatitis: Influence of hepatic metabolism versus portosystemic shunts on a patient complicated with HCC
-
Geier A, Gartung C, Dietrich CG, et al. Side effects of budesonide in liver cirrhosis due to chronic autoimmune hepatitis: Influence of hepatic metabolism versus portosystemic shunts on a patient complicated with HCC. World J Gastroenterol 2003;9:2681-5.
-
(2003)
World J Gastroenterol
, vol.9
, pp. 2681-2685
-
-
Geier, A.1
Gartung, C.2
Dietrich, C.G.3
-
87
-
-
80052435492
-
Budesonide for the treatment of autoimmune hepatitis
-
Snider KR, Potter TG. Budesonide for the treatment of autoimmune hepatitis. Ann Pharmacother 2011;45:1144-50.
-
(2011)
Ann Pharmacother
, vol.45
, pp. 1144-1150
-
-
Snider, K.R.1
Potter, T.G.2
-
88
-
-
77950327120
-
Rituximab in autoimmune hematologic diseases: Not just a matter of B cells
-
Stasi R. Rituximab in autoimmune hematologic diseases: Not just a matter of B cells. Semin Hematol 2010;47:170-9.
-
(2010)
Semin Hematol
, vol.47
, pp. 170-179
-
-
Stasi, R.1
-
89
-
-
84877603475
-
Rituximab for the treatment of patients with autoimmune hepatitis who are refractory or intolerant to standard therapy
-
Burak KW, Swain MG, Santodomino-Garzon T, et al. Rituximab for the treatment of patients with autoimmune hepatitis who are refractory or intolerant to standard therapy. Can J Gastroenterol 2013;27:273-80.
-
(2013)
Can J Gastroenterol
, vol.27
, pp. 273-280
-
-
Burak, K.W.1
Swain, M.G.2
Santodomino-Garzon, T.3
-
90
-
-
84873279968
-
Therapeutic effect of cytotoxic T lymphocyte antigen 4/immunoglobulin on a murine model of primary biliary cirrhosis
-
Dhirapong A, Yang GX, Nadler S, et al. Therapeutic effect of cytotoxic T lymphocyte antigen 4/immunoglobulin on a murine model of primary biliary cirrhosis. Hepatology 2013;57:708-15.
-
(2013)
Hepatology
, vol.57
, pp. 708-715
-
-
Dhirapong, A.1
Yang, G.X.2
Nadler, S.3
-
91
-
-
3442885909
-
Impairment of CD4(+) CD25(+) regulatory T-cells in autoimmune liver disease
-
Longhi MS, Ma Y, Bogdanos DP, et al. Impairment of CD4(+) CD25(+) regulatory T-cells in autoimmune liver disease. J Hepatol 2004;41:31-7.
-
(2004)
J Hepatol
, vol.41
, pp. 31-37
-
-
Longhi, M.S.1
Ma, Y.2
Bogdanos, D.P.3
-
92
-
-
84862658266
-
FOXP3+ regulatory T cells in autoimmune hepatitis are fully functional and not reduced in frequency
-
Peiseler M, Sebode M, Franke B, et al. FOXP3+ regulatory T cells in autoimmune hepatitis are fully functional and not reduced in frequency. J Hepatol 2012;57:125-32.
-
(2012)
J Hepatol
, vol.57
, pp. 125-132
-
-
Peiseler, M.1
Sebode, M.2
Franke, B.3
-
93
-
-
84872162712
-
Adoptive transfer of ex vivo expanded regulatory T cells in an autoimmune hepatitis murine model restores peripheral tolerance
-
Lapierre P, Beland K, Yang R, Alvarez F. Adoptive transfer of ex vivo expanded regulatory T cells in an autoimmune hepatitis murine model restores peripheral tolerance. Hepatology 2013;57:217-27.
-
(2013)
Hepatology
, vol.57
, pp. 217-227
-
-
Lapierre, P.1
Beland, K.2
Yang, R.3
Alvarez, F.4
-
94
-
-
39549122228
-
Expansion and de novo generation of potentially therapeutic regulatory T cells in patients with autoimmune hepatitis
-
Longhi MS, Meda F, Wang P, et al. Expansion and de novo generation of potentially therapeutic regulatory T cells in patients with autoimmune hepatitis. Hepatology 2008;47:581-91.
-
(2008)
Hepatology
, vol.47
, pp. 581-591
-
-
Longhi, M.S.1
Meda, F.2
Wang, P.3
-
95
-
-
79955980763
-
Natural killer T cells in health and disease
-
Wu L, Van Kaer L. Natural killer T cells in health and disease. Front Biosci (Schol Ed) 2011;3:236-51.
-
(2011)
Front Biosci (Schol Ed)
, vol.3
, pp. 236-251
-
-
Wu, L.1
Van Kaer, L.2
-
96
-
-
80052623696
-
Structure-guided design of an invariant natural killer T cell agonist for optimum protection from type 1 diabetes in non-obese diabetic mice
-
Blumenfeld HJ, Tohn R, Haeryfar SM, et al. Structure-guided design of an invariant natural killer T cell agonist for optimum protection from type 1 diabetes in non-obese diabetic mice. Clin Exp Immunol 2011;166:121-33.
-
(2011)
Clin Exp Immunol
, vol.166
, pp. 121-133
-
-
Blumenfeld, H.J.1
Tohn, R.2
Haeryfar, S.M.3
-
97
-
-
84862246208
-
Brief treatment with iNKT cell ligand alpha-galactosylceramide confers a long-term protection against lupus
-
Yang JQ, Kim PJ, Singh RR. Brief treatment with iNKT cell ligand alpha-galactosylceramide confers a long-term protection against lupus. J Clin Immunol 2012;32:106-13.
-
(2012)
J Clin Immunol
, vol.32
, pp. 106-113
-
-
Yang, J.Q.1
Kim, P.J.2
Singh, R.R.3
-
98
-
-
79953785705
-
Activation of natural killer T cells by alpha-carba-GalCer (RCAI-56), a novel synthetic glycolipid ligand, suppresses murine collagen-induced arthritis
-
Yoshiga Y, Goto D, Segawa S, et al. Activation of natural killer T cells by alpha-carba-GalCer (RCAI-56), a novel synthetic glycolipid ligand, suppresses murine collagen-induced arthritis. Clin Exp Immunol 2011;164:236-47.
-
(2011)
Clin Exp Immunol
, vol.164
, pp. 236-247
-
-
Yoshiga, Y.1
Goto, D.2
Segawa, S.3
-
99
-
-
0035742546
-
S-Adenosylmethionine modulates inducible nitric oxide synthase gene expression in rat liver and isolated hepatocytes
-
Majano PL, Garcia-Monzon C, Garcia-Trevijano ER, et al. S-Adenosylmethionine modulates inducible nitric oxide synthase gene expression in rat liver and isolated hepatocytes. J Hepatol 2001;35:692-9.
-
(2001)
J Hepatol
, vol.35
, pp. 692-699
-
-
Majano, P.L.1
Garcia-Monzon, C.2
Garcia-Trevijano, E.R.3
-
100
-
-
0344867846
-
S-adenosylmethionine in alcoholic liver cirrhosis: A randomized, placebo-controlled, double-blind, multicenter clinical trial
-
Mato JM, Camara J, Fernandez de Paz J, et al. S-adenosylmethionine in alcoholic liver cirrhosis: A randomized, placebo-controlled, double-blind, multicenter clinical trial. J Hepatol 1999;30:1081-9.
-
(1999)
J Hepatol
, vol.30
, pp. 1081-1089
-
-
Mato, J.M.1
Camara, J.2
Fernandez De Paz, J.3
|